Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T, Wu Q, Schloot NC et al. · The lancet. Diabetes & endocrinology · PMID 40609566
Study summary
Main finding
The substudy reported greater total fat-mass reduction in several retatrutide groups than placebo. Lean mass also decreased; its proportion of weight loss was similar to other obesity treatments.
A body-composition substudy enrolled 189 participants from the phase 2 diabetes trial; 103 completed treatment and both required DXA scans.
What the researchers measured
DXA imaging measured total fat mass and lean mass, with fat-mass change at week 36 the primary substudy outcome.
How to read this evidence
The paper includes research in people. Its comparison groups, participant selection, follow-up, and measured outcomes determine how far the findings can be applied. The label alone does not establish efficacy or safety.
Results in context
The analysis used a subset of the parent trial with available scans. Weight loss included lean mass loss; this is not an independent trial or proof that muscle is preserved.
What this does not establish
This shares the parent diabetes-trial population. Only 103 participants completed treatment and both DXA scans, limiting interpretation; it does not demonstrate muscle preservation or retail-product safety.
Publication & source
Why this paper is included
The compound is a named subject of the publication title.
Publication indexing
Journal Article · Randomized Controlled Trial · Clinical Trial, Phase II · Multicenter Study
Indexed subjects
Humans · Diabetes Mellitus, Type 2 · Male · Middle Aged · Female · Double-Blind Method · Body Composition · Adult · Aged · Hypoglycemic Agents · Glucagon-Like Peptides · Adolescent · Young Adult · Recombinant Fusion Proteins · Immunoglobulin Fc Fragments · Fatty Acids · Peptides
Source checked
October 4, 2026. Years follow journal issues; online-first dates may differ.